Laboratory of Molecular Pharmacology, Department of Pharmacy, Birla Institute of Technology and Science Pilani, Pilani Campus, Rajasthan 333031, India.
Division of Nephrology, Department of Internal Medicine IV, University Hospital of the Ludwig Maximilians University Munich, 80336 Munich, Germany.
Drug Discov Today. 2021 Aug;26(8):1963-1971. doi: 10.1016/j.drudis.2021.04.007. Epub 2021 Apr 20.
Diabetes and cardiorenal comorbidities are major global health concerns, with high economic burdens and mortality rates. Sodium glucose co-transporter-2 inhibitors (SGLT2is) are novel US Food and Drug Administration (FDA)-approved antihyperglycemics with unexpected protective potential against cardiorenal diseases in patients with or without type 2 diabetes mellitus (T2DM). Despite initial concerns, the incidence of episodes of acute kidney injury (AKI) was significantly lower in patients taking SGLT2i compared with other therapies or placebo. Evolving data suggest a link between SGLT2is and the anti-aging protein Klotho in the amelioration of diabetes and cardiorenal diseases. Here, we consider Klotho and SGLT2is as a novel therapeutic approach for the management of AKI and other cardiorenal complications in patients with or without diabetes.
糖尿病和心肾合并症是全球主要的健康关注点，具有较高的经济负担和死亡率。钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2i）是一种新型的美国食品和药物管理局（FDA）批准的抗高血糖药物，对有或没有 2 型糖尿病（T2DM）的患者的心肾疾病具有意外的保护作用。尽管最初存在一些担忧，但与其他治疗方法或安慰剂相比，服用 SGLT2i 的患者急性肾损伤（AKI）发作的发生率显著降低。不断发展的数据表明，SGLT2i 与抗衰老蛋白 Klotho 之间存在联系，可改善糖尿病和心肾疾病。在这里，我们将 Klotho 和 SGLT2i 视为一种新的治疗方法，可用于管理有或没有糖尿病的患者的 AKI 和其他心肾并发症。
